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Background: Metastasis-associated protein 1 (MTA1) has been associated with poor prognosis in several malignant
carcinomas. The purpose of this study was to investigate the expression and prognostic value of MTA1 in
nasopharyngeal carcinoma (NPC).
Methods: MTA1 expression was assessed using immunohistochemistry in paraffin-embedded tumor specimens
from 208 untreated NPC patients. Cox regression analysis was used to calculate the hazard ratio (HR), 95%
confidence interval (CI) and identify independent prognostic factors, and recursive partitioning analysis was used to
create a decision tree.
Results: Nuclear overexpression of MTA1 was observed in 48.6% (101/208) of the NPC tissues. Nuclear
overexpression of MTA1 correlated positively with N classification (P= 0.02), clinical stage (P= 0.04), distant
metastasis (P< 0.01) and death (P= 0.01). Additionally, nuclear overexpression of MTA1 correlated significantly with
poorer distant metastasis-free survival (DMFS; P <0.01) and poorer overall survival (OS; P< 0.01). MTA1 had
prognostic significance in NPC patients with stage II disease, but not stage III or IV disease. Multivariate analysis
demonstrated that nuclear overexpression of MTA1 was independently associated with poorer DMFS (HR, 2.05; 95%
CI, 1.13–3.72; P= 0.02) and poorer OS (HR, 1.98; 95% CI, 1.09–3.59; P= 0.03). Using recursive partitioning analysis, the
NPC patients could be classified with a low, intermediate or high risk of distant metastasis and death, on the basis
of clinical stage, age and MTA1 expression.
Conclusion: The results of this study suggest that nuclear overexpression of MTA1 correlates significantly with
poorer DMFS and poorer OS in NPC. MTA1 has potential as a novel prognostic biomarker in NPC.
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Nasopharyngeal carcinoma (NPC) is a unique type of
head and neck malignancy with an extremely unbalanced
endemic distribution. According to the International
Agency for Research on Cancer, there were an estimated
84,400 incident cases of NPC and 51,600 deaths due to
NPC in 2008, with 40% of these occurring in Chinese
individuals [1]. Due to anatomic constraints and the high* Correspondence: majun@sysucc.org.cn
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reproduction in any medium, provided the orradiosensitivity, NPC is mainly treated with radiotherapy.
Although recent advances in diagnosis and therapy have
significantly improved treatment outcomes, distant me-
tastasis still occurs in 20–30% of patients and becomes
the major cause of death in NPC [2].
Currently, prediction of the risk of distant metastasis in
NPC is still reliant on the TNM staging system; however,
varying outcomes are observed in patients with the same
stage of disease who receive similar therapies, indicating
that some NPC patients may be benefit from more aggres-
sive treatments, while others could potentially be spared
the toxicity of unnecessary chemotherapy. Although several
biomarkers have been associated with prognosis in NPC,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of great clinical value to identify novel biomarkers which
could be utilized as effective prognostic predictors or pos-
sible therapeutic targets, in order to optimize the treatment
of patients with NPC.
The metastasis-associated protein (MTA) family is a
group of structurally related proteins encoded by the same
or different genes, including MTA1, MTA1s, MTA-
ZG29p, MTA2, MTA3, and MTA3L [4,5]. MTA proteins
physically interact with histone deacetylase 1 (HDAC1)
and HDAC2 to form the nucleosome remodeling and his-
tone deacetylation (NuRD) protein complex, which is
involved in chromosome remodeling, histone deacetylation
and transcriptional regulation [6,7]. As a major member of
the MTA family, the MTA1 gene was first identified by dif-
ferential screening of cDNA libraries constructed from
highly metastatic and nonmetastatic mammary adenocar-
cinoma cell lines [8,9]. Experimental studies have shown
that MTA1 may play an important role in carcinogenesis
and cancer progression, including malignant transform-
ation, angiogenesis, invasion and metastasis, by interacting
with various cell signaling pathways [4,5,10]. MTA1 is
upregulated in diverse human malignancies, including car-
cinoma of the stomach, esophagus, prostate, breast, liver,
oral cavity, lung and colorectum, and is associated with
tumor progression, lymph node metastasis and poor prog-
nosis [11-20]; however, little is known about the expression
level and prognostic value of MTA1 in NPC.
Therefore, in this report, we studied the expression pat-
tern of MTA1 in tumor samples from NPC patients, and
analyzed the association between MTA1 expression and
the clinicopathological characteristics of NPC. In addition,
we evaluated the prognostic value of MTA1, in order to
develop more personalized therapy for NPC patients.
Methods
Patient and tissue specimens
A total of 208 pretreatment paraffin-embedded NPC spe-
cimens were collected from the archives of the Depart-
ment of Pathology of the Cancer Center of Sun Yat-sen
University between January 2004 and February 2006.
The cases were selected on the basis of the following cri-
teria: histologically proven NPC with available biopsy
specimens, newly diagnosed and non-distant metastatic
NPC; no treatment history or other malignant disease;
Karnofsky score ≥70; received radiotherapy at our Can-
cer Center and follow-up regularly. The study was
approved by the Institutional Research Ethics Committee
and written informed consent was obtained from each
participant. All medical records were reviewed retro-
spectively and all patients were restaged according to the
7th edition of the UICC/AJCC system [21]. All 208
patients were pathologically diagnosed with World
Health Organization type II or III NPC, and theclinicopathological characteristics of the patients are
summarized in Table 1.
Treatment and follow-up
All patients received definitive radiotherapy: 160/208
(76.9%) patients were treated with two-dimensional radio-
therapy (2D-RT) and 48/208 (23.1%) patients were treated
with intensity-modulated radiotherapy (IMRT). Details of
the radiation therapy techniques applied at the Cancer
Center of Sun Yat-Sen University have been reported pre-
viously [2]. During the study period, the institutional
guidelines recommended no chemotherapy for stage I to
IIa patients, concurrent chemoradiotherapy for stage IIb
patients, and concurrent chemoradiotherapy with or with-
out neoadjuvant/adjuvant chemotherapy for stage III to
IVa-b patients, as defined by the 6th edition of the UICC/
AJCC staging system for NPC. Concurrent chemotherapy
consisted of cisplatin administered on weeks 1, 4 and 7 of
radiotherapy, or weekly. Neoadjuvant and adjuvant
chemotherapy consisted of cisplatin with 5-fluorouracil or
taxanes every three weeks for three cycles. Overall, 62.5%
(40/64) of the stage IIB patients and 84.1% (116/138) of
the stage III-IV patients received chemotherapy.
The median follow-up period for the entire cohort was
62.4 months (range, 5.2–79.9 months). The 5-year over-
all survival (OS), distant metastasis-free survival (DMFS)
and locoregional relapse-free survival rates were 78.4%,
76.7% and 87.4%, respectively.
Immunohistochemistry (IHC)
Expression of MTA1 was examined using IHC in tissue
sections from 208 cases of human NPC. The sections
were deparaffinized in xylene, rehydrated through graded
alcohols, immersed in 3% hydrogen peroxide for 30 min
to quench endogenous peroxidase activity, and micro-
waved in EDTA antigen retrieval buffer. Nonspecific
binding was blocked with 1% bovine serum albumin at
room temperature for 20 min, then the sections were
incubated with anti-MTA1 mouse monoclonal antibody
(1:500 dilution; Abcam, Cambridge, UK) overnight at 4°
C in a humidified chamber. Negative controls were per-
formed by replacing the primary antibody with normal
goat serum. After washing, the tissue sections were incu-
bated with biotinylated anti-mouse secondary antibody
for 30 min at room temperature followed by streptavi-
din-horseradish peroxidase complex for 20 min, stained
with 3, 3-diaminobenzidine (DAB), counterstained with
hematoxylin, dehydrated and mounted.
IHC scoring
The degree of immunohistochemical staining was evaluated
independently by two clinical pathologists who were
blinded to the clinicopathological data, and any differences
were discussed until consensus was reached. MTA1 nuclear
Table 1 Correlation between the nuclear expression levels of MTA1 and the clinicopathological characteristics of
nasopharyngeal carcinoma patients
Characteristic No. of patients MTA1 Nuclear Expression Chi-square test
Low, n(%) High, n(%) P value
Sex 0.93
Male 155 80 (51.6%) 75 (48.4%)
Female 53 27 (50.9%) 26 (49.1%)
Age(y) 0.86
≤ 50 129 67 (51.9%) 62 (48.1%)
> 50 79 40 (50.6%) 39 (49.4%)
T classification 0.07
T1-T2 104 60 (57.7%) 44 (42.3%)
T3-T4 104 47 (45.2%) 57 (54.8%)
N classification 0.02
N0-N1 130 75 (57.7%) 55 (42.3%)
N2-N3 78 32 (41.0%) 46 (59.0%)
Clinical stage 0.04
I-II 70 43 (61.4%) 27 (38.6%)
III-IV 138 64 (46.4%) 74 (53.6%)
Locoregional failure 0.61
No 185 94 (50.8%) 91 (49.2%)
Yes 23 13 (56.5%) 10 (43.5%)
Distant metastasis <0.01
No 159 90 (56.6%) 69 (43.4%)
Yes 49 17 (34.7%) 32 (65.3%)
Death 0.01
No 160 90 (56.2%) 70 (43.8%)
Yes 48 17 (35.4%) 31 (64.6%)
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ing system incorporating the proportion of positively
stained tumor cells (0, ≤5%; 1, 6–25%; 2, 26–50%; 3, 51–
75%; 4, ≥76%) and the intensity of staining (0, no staining;
1, light yellow weak staining; 2, yellow brown moderate
staining; 3, brown strong staining) to result in a score of 0,
1, 2, 3, 4, 6, 8, 9 or 12. The cutoff value for high- and low-
expression was selected on the basis of a measure of het-
erogeneity using the log-rank test statistical analysis with
respect to overall survival. The optimal cutoff value was
defined as 4: tumors with scores≤ 4 were defined as low
MTA1 expression, while tumors with scores> 4 were
designated as high MTA1 expression.Statistical analysis
The χ2-test was used to analyze the correlation between
MTA1 expression and clinicopathological features. The ac-
tuarial rates were calculated using the Kaplan-Meier
method [22] and differences were compared using the log-
rank test. Multivariate analysis using the Cox proportionalhazards model [23] was performed to calculate the hazard
ratio (HR), 95% confidence interval (CI) and to test inde-
pendent significance by backward elimination of insignifi-
cant variables. Covariates included host factors (i.e., sex,
age), therapeutic intervention (i.e., radiotherapy technique,
chemotherapy) and tumor factors (i.e., T classification, N
classification, clinical stage). These analyses were per-
formed using Statistical Package for the Social Sciences
(SPSS) v13.0 (Chicago, IL, USA); two-tailed P-values< 0.05
were considered statistically significant. Recursive parti-
tioning analysis was performed to construct prognostic
models using the significant variables from the multivariate
analysis. R software (R version 2.14.1; rpart package version
3.1–51, http://www.r-project.org/) was used to create a de-
cision tree with split criteria, based on the log-rank test.Results
Expression of MTA1 in NPC
Representative images of MTA1 immunohistochemical
staining in NPC tissues are shown in Figure 1A-D. Positive
Figure 1 Immunohistochemical analysis of MTA1 protein expression in nasopharyngeal carcinoma tissues. MTA1 protein expression was
mainly localized within the nucleus. (A) Negative staining (400×); (B) weak staining: light yellow (400×); (C) moderate staining: yellow brown
(400×); (D) strong staining: brown (400×); (E) MTA1 protein expression was upregulated in the nasopharyngeal carcinoma tissue (solid arrow)
compared to the adjacent noncancerous epithelial cells (hollow arrow).
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High nuclear expression of MTA1 was detected in 48.6%
(101/208) of the NPC tissues, while weak or no nuclear
MTA1 staining was observed in the adjacent noncancerous
epithelial cells. As shown in Figure 1E, MTA1 was overex-
pressed in the nuclei of NPC cells compared to the adja-
cent normal epithelial cells in the same section.Correlation between MTA1 expression and the
clinicopathological features of NPC
Table 1 shows the relationship between MTA1 protein
expression and the clinicopathological characteristics of
NPC patients. Nuclear overexpression of MTA1 corre-
lated positively with N classification (P= 0.02), clinical
stage (P= 0.04), distant metastasis (P< 0.01) and death
(P= 0.01). However, there was no significant correlation
between MTA1 expression and other clinicopathologicalTable 2 Univariate analysis of the significance of different pro
Factors DMFS
P value HR
Age (>50 yr vs. ≤50 yr) 0.02 1.90
Sex (female vs. male) 0.82 0.93
Chemotherapy (yes vs. no) 0.14 1.78
Radiotherapy (IMRT vs.2D-RT) 0.99 1.00
T stage (T3–4 vs. T1–2) 0.13 1.55
N stage (N2–3 vs. N0–1) 0.02 1.98
Clinical stage (III-IV vs. I-II) 0.01 2.52
MTA1 expression (high vs. low) <0.01 2.25
Abbreviation: DMFS distant metastasis free-survival; OS overall survival; IMRT intensicharacteristics, such as age, gender, T classification or
locoregional failure (P> 0.05).Univariate analysis
Gender, radiation technique, chemotherapy and T classifi-
cation had no significant impact on DMFS or OS in uni-
variate analysis (P> 0.05). In contrast, age, N classification,
clinical stage and MTA1 expression could significantly
predict DMFS and OS (P< 0.05; Table 2). Kaplan-Meier
analysis revealed that nuclear overexpression of MTA1
correlated significantly with poorer DMFS (HR, 2.25; 95%
CI, 1.25–4.05; P< 0.01) and poorer OS (HR, 2.19; 95% CI,
1.21–3.97; P< 0.01; Figure 2A).
We further analyzed the prognostic value of MTA1 in
subgroups of NPC patients stratified according to clinical
stage. As only 6 patients had stage I disease, the stratified
analysis was performed in stage II-IV patients. In thegnostic variables in nasopharyngeal carcinoma
OS
95% CI P value HR 95% CI
1.09–3.35 <0.01 2.15 1.22–3.81
1.48–1.78 0.66 0.86 0.44–1.69
0.83–3.79 0.26 1.52 0.73–3.13
0.80–1.25 0.93 1.01 0.81–1.26
0.88–2.74 0.06 1.77 0.99–3.18
1.13–3.47 0.01 2.06 1.17–3.63
1.22–5.19 <0.01 2.78 1.30–5.95
1.25–4.05 <0.01 2.19 1.21–3.97
ty-modulated radiotherapy; 2D-RT two-dimensional radiotherapy.
Figure 2 Kaplan-Meier distant metastasis-free survival and overall survival curves for nasopharyngeal carcinoma patients stratified by
MTA1 expression level and clinical stage. (A) Stage I-IV patients (n = 208); (B) Stage II patients (n = 64); (C) Stage III patients (n = 63); (D) Stage IV
patients (n = 75). HR: hazard ratio; CI: confidence interval.
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MTA1 had significantly poorer DMFS (HR, 5.92; 95% CI,
1.23–28.55; P=0.03) and poorer OS (HR, 5.07; 95% CI,
1.02–25.19; P=0.05) than patients with lower levels of
MTA1 expression (Figure 2B). However, the OS and
DMFS of stage III or IV patients with low and high MTA1
expression were not significantly different (Figure 2C-D).
Multivariate analysis
Multivariate analysis, which included age (>50 yr vs.
≤50 yr), sex (female vs. male), radiotherapy (IMRT vs.
2D-RT), chemotherapy (yes vs. no), clinical stage (stage
III-IV vs. I-II) and the MTA1 protein expression level
(high vs. low), was performed to identify independent
prognostic factors. The expression level of MTA1 was an
independent prognosticator for DMFS (HR, 2.05; 95%
CI, 1.13–3.72; P= 0.02) and OS (HR, 1.98; 95% CI, 1.09–
3.59; P= 0.03). From the other variables, age and clinical
stage were also found to be independent prognostic fac-
tors for DMFS and OS (Table 3).
Recursive partitioning analysis
Recursive partitioning analysis was performed to con-
struct a decision tree, using the significant independent
prognostic factors for DMFS and OS including age, clin-
ical stage and MTA1 expression. The same decision tree
was produced using distant failure and death as end-
points (Figure 3A-B). Based on the HR calculated in each
terminal node, we classified the patients into low, inter-
mediate and high risk groups, with 5-year DMFS and OS
rates of 89.8% and 90.6%, 67.6% and 73.3%, 46.4% and
42.6%, respectively. Significant differences were observed
between the groups (Figure 3C-D). Compared with the
low risk group (HR= 1), the intermediate risk group and
the high risk group both had significantly higher HRs for
DMFS and OS (P< 0.01).
Discussion
The recognition that cancers of the same clinical stage
have divergent prognoses and respond differently to the
same therapeutic intervention has promoted the study of
prognostic markers, which is particularly important forTable 3 Multivariate analysis of the significance of different p
Factors DMFS
P value HR
Age (>50y vs. ≤50y) 0.02 1.91
Sex (female vs. male) 0.88 1.05
Chemotherapy (yes vs. no) 0.39 1.42
Radiotherapy (IMRT vs.2D-RT) 0.65 0.95
Clinical stage (III-IV vs. I-II) 0.03 2.21
MTA1 expression (high vs. low) 0.02 2.05
Abbreviation: DMFS distant metastasis free-survival; OS overall survival; IMRT intensithe development of personalized therapy. In the present
study, we observed that the nuclear expression levels of
MTA1 correlated significantly with the clinical stage and
survival of NPC patients. In addition, MTA1 was identi-
fied as an independent prognosticator in multivariate
analysis, indicating that MTA1 has potential as a novel
prognostic biomarker to guide clinical practice and re-
search on NPC.
The majority of NPC deaths are attributed to tumor
metastases, rather than local failure. As a metastasis-
associated protein, overexpression of MTA1 has been
demonstrated in a range of malignant tumors and is
strongly associated with cancer cell invasion and migra-
tion. Moreover, overexpression of MTA1 has been clinic-
ally linked to advanced clinical stage, lymph node
metastasis and poor prognosis [11-20]. Recently, Deng
et al. used in situ hybridization to detect the expression
of MTA1 mRNA in NPC. The positive rate of MTA1 ex-
pression was significantly higher in NPC and metastatic
lymph node tissues than chronic nasopharyngitis tissues,
and the expression level of MTA1 mRNA correlated
positively with lymph node metastasis, tumor recurrence
and death; however, the prognostic significance of MTA1
was not investigated [24].
In this study, we examined the expression of MTA1 in
paraffin-embedded NPC biopsies using immunohisto-
chemical staining. We observed that 48.6% of the speci-
mens expressed high levels of MTA1 in the tumor cell
nuclei, while MTA1 was absent or expressed weakly in
the nuclei of the adjacent noncancerous epithelial cells.
We also showed that nuclear overexpression of MTA1
correlated significantly with advanced N classification
and clinical stage as well as distant metastasis and death,
but not with T classification or locoregional failure.
These findings strongly suggest that MTA1 may play an
important role in the development and progression of
NPC.
Furthermore, nuclear overexpression of MTA1 was asso-
ciated with poorer DMFS and poorer OS in both univariate
and multivariate analysis, suggesting that nuclear overex-
pression of MTA1 is an unfavorable prognostic factor in
NPC. It is noteworthy that the prognostic value of MTA1rognostic variables in nasopharyngeal carcinoma
OS
95% CI P value HR 95% CI
1.09–3.34 0.01 2.11 1.19–3.74
0.54–2.05 0.99 1.00 0.50–2.01
0.64–3.11 0.62 1.21 0.57–2.58
0.76–1.19 0.67 0.95 0.76–1.20
1.06–4.59 0.02 2.44 1.13–5.25
1.13–3.72 0.03 1.98 1.09–3.59
ty-modulated radiotherapy; 2D-RT two-dimensional radiotherapy.
Figure 3 (A) Recursive partitioning analysis of distant metastasis-free survival in all nasopharyngeal carcinoma (NPC) patients; (B)
recursive partitioning analysis of overall survival in all NPC patients; (C) Kaplan-Meier distant metastasis-free survival curves in the
classified patients; (D) Kaplan-Meier overall survival curves in the classified patients. HR: hazard ratio; CI: confidence interval.
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analysis, but not stage III or IV patients. In order to com-
bine MTA1 with known robust clinical prognostic factors,
we established a recursive partitioning tree consisting of
MTA1, clinical stage and age, which were independent
prognostic factors for DMFS and OS in multivariate ana-
lysis. The study population could be segregated into three
distinct prognostic groups: MTA1 had specific prognostic
value in patients with stage I-III disease, while age was eval-
uated as the most important prognosticator in the stage IV
subgroup.
Our results indicate that the prognostic value of
MTA1 is most significant in early-stage NPC patients,
especially those with stage II disease, and similar findings
have also been reported in other types of cancer [18,20].
According to the National Comprehensive Cancer Net-
work guidelines, NPC patients with stage II disease
should receive concurrent chemoradiotherapy followed
by adjuvant chemotherapy. However, excellent survival
rates for stage II NPC patients treated with concurrent
chemoradiotherapy alone have been reported recently[25], indicating that some patients could possibly be
spared from the toxicity and cost of unnecessary adju-
vant chemotherapy. The results of this study suggest that
MTA1 may provide an effective prognostic index to
identify individuals with a poor prognosis, and help to
stratify the need for adjuvant chemotherapy in stage II
NPC patients.
Further investigation of the function and mechanism
of action of MTA1 may provide additional targets and
strategies for the treatment of NPC. To date, MTA1 has
been demonstrated to be involved in multiple signaling
pathways, which contribute to several aspects of the
metastatic phenotype by modifying the acetylation status
of crucial target genes [4,5,10]. Yoo et al. reported that
MTA1 induced the deacetylation and enhanced the stability
of hypoxia-inducible factor-1α (HIF-1α) by recruiting
HDAC1 in breast cancer cells, which indicates that a close
connection may exist between MTA1-associated metastasis
and HIF-1α-induced tumor angiogenesis [26]. Kai et al.
identified MTA1 as a component of a bone metastasis sig-
nature in prostate cancer, and MTA1-knockdown cells
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(VEGF) and displayed decreased angiogenicity both in vitro
and in vivo [27], suggesting that MTA1 upregulates VEGF
expression, in agreement with Du et al. [19]. Correlations
between the expression of MTA1 and matrix metalloprotei-
nase 9 [28], E-cadherin [29] and the cellular cytoskeleton
components [30] have also been reported by different
researchers.
The mechanisms leading to the upregulation of MTA1
protein expression in human cancers are not known.
Zhang et al. reported that MTA1 was an essential down-
stream effector of the c-MYC oncoprotein and regulated
the epithelial-to-mesenchymal transition (EMT) process
[31]. Recently, Lee et al. reported that a MTA1 IVS4-
81 G/A single nucleotide polymorphism (SNP) and
VEGF +12916C SNP were associated with overexpres-
sion of MTA1 in hepatocellular carcinoma tissues [32].
Our study suggests that MTA1 plays an important role
in the development and progression of NPC; however,
further investigation is required to clarify its mechanism
of action and determine the precise signaling pathways
by which MTA1 regulates metastasis in NPC.
Conclusions
In summary, this study revealed the expression pattern of
MTA1 in NPC, and demonstrated that high levels of nu-
clear MTA1 expression correlated significantly with poorer
DMFS and OS in NPC, especially in patients with stage II
disease. Furthermore, incorporation of MTA1 with age
and clinical stage enabled the classification of NPC
patients into groups with a low, intermediate, or high risk
of distant metastasis and death using recursive partitioning
analysis. Our results suggest that upregulation of MTA1
may be important for the acquisition of a poor prognostic
phenotype in NPC. However, these findings need to be
replicated in a different patient population, and further
studies are needed to clarify the mechanism by which
MTA1 is involved in the development and progression of
NPC.
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